特利加压素治疗慢性重型肝炎并发肝肾综合征的疗效观察

Effect of Terlipressin on Patients with Chronic Severe Hepatitis Accompanied by Hepatorenal Syndrome

目的:观察特利加压素治疗重型肝炎并发肝肾综合征的疗效。方法:12例重型肝炎患者分为两组,对照组仅给予综合治疗,治疗组在综合治疗基础上加用特利加压素,剂量为1mg静脉注射,q12h,疗程4～8天。结果:治疗组患者临床症状改善明显优于对照组;治疗后治疗组尿量为(2202±785)ml,对照组为(963±711)ml;治疗后血肌酐水平治疗组为(74.6±33.3)μmol/L,对照组为(182.9±82.3)μmol/L;疗程结束后对照组患者5例死亡或自动出院,1例好转,治疗组5例好转,1例死亡。结论:特利加压素治疗肝肾综合征可改善患者临床症状及预后,降低血肌酐水平,增加尿量,为治疗该病提供新的措施。

Objective: To observe the effect of Terlipressin on patients with chronic severe hepatitis (CSH) accompanied by hepatorenal syndrome (HRS) .Methods: 12 patients were divided into 2 groups, controlled group treated with compositive treatments, in therapeutic group Terlipressin was added. Dosage regimens were Terlipressin 1 mg q12h given with injection of vein.Duration of treatment was 4-8 days.Results: After the course the clinical syndrome in therapeutic group improved more than controlled group; Urine volume of therapeutic group was (2202±785) ml, controlled group was (963±711) ml; Blood creatinine of therapeutic group was (74.6±33.3) μmol/L, controlled group was (182.9 ±82.3) μmol/L; In controlled group 5 patients died or automatically discharged, in therapeutic group 5 patients improved and 1 patient died.Conclusion: Terlipressin improved the clinical syndromes and prognosis of patients with hepatorenal syndrome (HRS), reduced the level of blood creatinine, increased the urine volume.Terlipressin will provid us a new way to treat patients with hepatorenal syndrome (HRS) .